“Our country has a vast knowledge base of Ayurveda whose potential is only being realised in the recent years. However, the drug delivery system used for administering the medicine to the patient is traditional and out-of-date resulting in reduced efficacy of the drug,” remarked Sourav Roy, Managing Director, Asoka Lifescience Limited. “We thought of coming up with a unique remedy of respiratory problems by blending the best of both- the tradition of Ayurveda and the technology of modern medicine.”

The drug is the outcome of rigorous research and development undertaken by the Department of Pharmaceutical Technology, Jadavpur University. Abbies Webiana, a universally prescribed herb for respiratory distress is one of the key ingredients of Res-Q. Based on a poly-herbal composition, Res-Q is a mouth dissolving drug that mixes with the juices secreted by the salivary glands and dissolves completely within fifteen minutes of putting in the mouth. Thus the drug never makes it to the stomach and the vital constituents are not absorbed by the various digestive juices secreted within the metabolic system of the body.

“Our country has the second highest mortality rate of asthma, one of the primary respiratory ailments we are targeting,” Mr. Roy went on to say. “We don’t claim our product to be a miracle drug that will cure asthma completely, but we are quite confident that Res-Q will ensure relief from attacks much faster and minimize them in the long run if taken on a regular basis.”

Res-Q comes in a strip of ten tablets, moderately priced to make it affordable among all the sections of the society. Many other research based drugs for chronic as well as fatal ailments are lined up for launch in the coming months.

The drug has been distributed among all the major chemist shops throughout the state of West Bengal and an entire team of aggressive sales professionals has been formed to meet the needs of distributors across the state. Besides the conventional marketing strategies, a non-profit organization called Asoka Welfare Society has also been formed up and ahelpline has been formed where queries on asthma and other respiratory ailments will be answered.The concerned person needs to send an SMS. He/she must write 'LUNG' and send it to 5676775. The associates of Asoka Welfare Society will get back to the person within 48 hours.

Source: Press release distribution via India PRwire

Ambassador Teresita Schaffer, Director of the South Asia Program of the Center for Strategic and International Studies, is the Chief Guest. (See biographical information below.) Energizing Entertainment will be provided by Funkadesi, a Chicago based band ranked as “the best world music group” by the Chicago Reader’s 2008 Reader’s Choice Awards. This five

time winner of The Chicago Music Awards, “bears the message of togetherness…with rhythms of Indian Ragas and reggae, spiced with Latin, African, and contemporary funk…” (Toronto Star). Singer and physician Manohar Jethani will join the band as special guest.

The event will be held at the lovely Waterford Banquet and Conference Halls, 933 S. Riverside Drive, Elmhurst, IL 60126, beginning at 5:30 pm with reception and Silent Auction. Ticket price includes delicious South Asian buffet dinner, ceremony to honor guests, and an evening of invigorating and beautiful music, with dancing optional. Participation supports programs of health care and development in India.

For ticket purchases, to reserve space in the Program Book, or to donate items for the Silent Auction, please contact:

Kathy Evers, Event Coordinator: Phone: 708-707-4428, Email: kaevers@sbcglobal.net, or

Linda Groetzinger, Co-Coordinator: Phone: 773-484-0883, Email: lgroetzinger@yahoo.com

About Ambassador Teresita Schaffer, Chief Guest (from www.csis.org):

Ambassador Teresita Schaffer came to CSIS in August 1998 after a 30-year career in the U.S. Foreign Service. She devoted most of her career to international economic issues and to South Asia, on which she was one of the State Department’s principal experts.

From 1989 to 1992, she served as deputy assistant secretary of state for South Asia, at that time the senior South Asia position in the department; from 1992 to 1995, she was the U.S. ambassador to Sri Lanka; and from 1995 to 1997, she served as director of the Foreign Service Institute. Her earlier posts included Tel Aviv, Islamabad, New Delhi, and Dhaka, as well as a tour as director of the Office of International Trade in the State Department. She spent a year as a consultant on business issues relating to South Asia after retiring from the Foreign Service.

Her publications include “Sri Lanka: Lessons from the 1995 Negotiations,” in Creating Peace in Sri Lanka (Brookings, 1998); two studies on women in Bangladesh; and “Kashmir: Fifty Years of Running in Place,” in Grasping the Nettle (USIP, 2004). Her CSIS publications include Kashmir: The Economics of Peace Building (2005), Pakistan’s Future and U.S. Policy Options (2004), Rising India and U.S. Policy Options in Asia (2002), and several reports on the HIV/AIDS epidemic in India. Schaffer has taught at Georgetown University and American University. She speaks French, Swedish, German, Italian, Hebrew, Hindi, and Urdu, and has studied Bangla and Sinhala.

This event supports the work of the collaborating organizations working principally in India:

The Ribbon Foundation, SHARE/International Center for Human Health Advancement and Care and Share Foundation

Source: Press release distribution via India PRwire

CARE AND SHARE FOUNDATION: Mission: “To foster health care for the poor and needy; education, research,…and growth and availability of quality health care services …; coordinate and support activities of not-for-profit organizations engaged in the betterment of mankind by providing educational assistance, shelters for the homeless, etc; promote and advance relationships between … health care providers and communities, esp. in the area of HIV/AIDS awareness and prevention; and organize Volunteer medical Missions. Contact: Firdaus Jafri, DDS, phone: 630 665 2147. THE RIBBON FOUNDATION Mission: “To make a difference… in the lives of the sick, disabled, suffering and needy, …by providing resources, sharing knowledge, building common understanding, and creating awareness, nationally and internationally.” Contact: Manohar Jethani, M.D., SHARE/International Center for Human Health Advancement “Health is a basic human right integral to all spheres of human development. Mission: to provide affordable comprehensive health care; educate and train health care professionals and the community; support research using technologic, social, & cultural tools for advancement of human health; and to provide a forum for international collaboration.” Contact: Vijay Yeldandi, M.D.,

St Botanica products are completely herbal and have no side effects. You don’t need to worry about ugly scars that are a by product of surgery or any other ailments. The exclusive range of Breast products includes Nano Breast Cream, St Botanica Breast Cream for enhancement, Breast serum, Breast Spray and Breast capsules. Lady secret Serum is a vaginal product for tightening and restoring your beauty.

Sahil Mehta, owner and brand ambassador of St Botanica, says, “Some of the St Botanica products have been developed by using nanotechnology, a breakthrough in the world of cosmetics. This avante garde technology is being launched in cosmetics for the first time in Indian markets and is all set to take the industry by storm. This tried and tested technology is void of any side effects and gives the Indian woman a chance to enhance her figure and beauty.”

What’s more…? Women can even interact with experts online at www.stbotanica.in and express their views and share their experiences. 24 hour customer care executives will be available to help you at all hours and answer questions related to your beauty queries. This unique platform extends the opportunity of supplying not only the ultimate line of St Botanica products but will also enable women come forward and interact.

So, explore your feminine charm and get a ravishing figure with St Botanica Cosmetics. Now, you can forget your ageing blues and rely on the world’s most trusted cosmetics to enhance your youth and beauty.

Source: Press release distribution via India PRwire

Customers availing of services worth Rs. 1,000/- and above get to spin the “Wheel of Fortune” to win savings up to 100%* of their billing (terms & conditions applicable). Apart from this, special discounts have been offered on various MCC products like the Fair & Square Combo, the Ageless Combo and the Amazing Combo. Other special offers include a 25% off on select products like Snorben (an anti-snoring device), Pedometers, Digital Thermometers, etc. A 10% discount is being offered on the Osim range of products as well as a discount ranging from Rs. 7,500/- upto Rs. 25,000/- is being offered on Power Plate products, depending on the product purchased.

The Anniversary offers are available from August 3rd to August 31st, 2008 at all the centers of MCC in Ahmedabad, Bengaluru, Mumbai and Pune.

Source: Press release distribution via India PRwire

About Manipal Cure & Care

Manipal Cure & Care is an initiative of Manipal Education and Medical Group (MEMG). Founded by the late Padmashree Dr. T.M.A. Pai in 1953, Manipal Education and Medical Group today stands tall with an enviable track record of success in the spheres of Healthcare, Education and Research nationally and internationally. Its operations are spread across India, Middle East and several Southeast Asian countries.

The integrated Manipal Cure and Care (MCC) centres offer a mix of world-class products and services in preventive, wellness and beauty care. They are the first in India to provide qualitative monitoring of healthcare driven by well-trained doctors and paramedical staff. They offer health services that are customized based on each individual’s lifestyle and family medical history.

Manipal Cure & Care builds on the experience, know-how and socially beneficial vision of the Manipal Education and Medical Group itself. This pioneering venture introduces to India the concept of holistic Health and Wellness care in a retail format, providing superior clinical services with related product offerings, all under one roof!

Performance highlights for the Quarterly results

- Sales/Income from Operations stood at Rs. 2139.64 lacs during the quarter ended 30th June, 2008 as against Rs.1833.60 lacs in the previous year’s quarter for the same period, thereby registering a growth of 17%.

- Profit before tax stood at Rs. 165.57 lacs during the quarter ended 30th June, 2008 as against Rs.85.39 lacs in the previous year’s quarter for the same period, thereby registering a growth of 94%.

- EBIDTA stood at Rs. 381.22 lacs during the quarter ended 30th June, 2008 as against Rs.253.58 lacs in the previous year’s quarter for the same period, thereby registering a growth of 50%.

Mr. Ashish Dandekar, Managing Director of the company commented on the results, “The combination of strong R&D and Technological support and a boost in demand from the growth in domestic and global food industry and also growth in Ediable Oil demand have helped the company to reflect such an impressive performance in the 1st Quarter ending 30th June 2008 in the current year. With a customer base spread across 45 countries and multiple product sectors, we expect the growth to continue.”

“Our strategic approach of enhancing our product basket has begun to pay off and we will continue with strong product development, process development and business support to enhance our market share.”

Source: Press release distribution via India PRwire

About Camlin Fine Chemicals Ltd.

Camlin Fine Chemicals Ltd. is focused on a vision to be the largest food antioxidant and ingredient manufacturer worldwide. CAMLIN FINE CHEMICALS LTD. will achieve the mission by placing the needs of our customers first, creating quality products, innovating technology, and fostering continuous improvements in our people, products and processes.

CAMLIN FINE CHEMICALS LTD. believes in building the business on basic values:

· A focused approach towards manufacturing our products

· Hard work and excellence in all our efforts

· Team work across functions

For further information contact: CMCG India – Ms. Suparna C Ganguly @ 022 2445 0991, Email – suparna.ganguly@cmcgindia.com

The seminar will be addressed by Dr. Patki – Vice President, Himalaya Drugs, Dr. Patki, has submitted over 60 clinical research papers that have appeared in various national and international journals. Dr Patki, will focus on the scope, importance and career opportunities for people specialising in clinical trials. For further information and registration, please call 044 – 4266 2360 / 4351 0911 / 9944803826

Clinical research is poised to be the next big revenue earner for the country. It is estimated to grow into US$ 1 billion strong industry in India by 2010 with 50000 clinical research jobs in India and 2,50,000 jobs worldwide.

Manipal University with 50yrs of experience in health and education has been offering this course to cater to the growing needs of the industry. This course is conducted at Chennai and developed jointly by experts from industry and academia.

Admissions for the current academic year for Manipal’s Diploma in Clinical Research and Regulatory Affairs at Manipal University are also currently open.

The Application Form is available at Manipal Universal Learning's office or can be downloaded from the website. For more details on the programs and admissions please visit www.crra.manipal.edu

Source: Press release distribution via India PRwire

About Manipal University

Manipal University was recognized by the Government of India as a deemed to be University in the year 1993. Among the foremost colleges and Institutions in India, the Manipal University colleges are highly regarded in their sphere of expertise, be it MIT (Manipal Institute of Technology) for engineering, or KMC (Kasturba Medical College) for medicine. Manipal University today ranks as one of India's premier multi-dimensional educational institutions and the awarding of a Deemed University status is testimonial to this fact.

Students from over 52 countries worldwide come seeking education in this culturally diverse institute. Degrees from Manipal are recognized worldwide, making it a Mecca of educational services.

About Manipal Educatio

Manipal Education is one of the largest education services providers from India. The group includes two universities, Manipal University & Sikkim Manipal University, and over 30 other institutions in India, besides colleges and university campuses in Antigua, Dubai, Malaysia and Nepal. Manipal Education currently has over 135,000 students from over 50 countries, of which about 25,000 students study at institutions and overseas campuses in India and abroad, while over 110,000 students undertake distance education, delivered using a blended approach including both satellite-based lectures and local coaching at 550 learning centres in India and overseas. Manipal Education also offers online testing and assessment for academic as well as corporate clients, and has recently launched professional education for service sectors like financial services, IT, media and retail.

Manipal Education recently partnered with ICICI a leading financial services group in establishing the ICICI Manipal Academy of Banking & Insurance. The academy is expected to expand the pool of industry ready resources and provide inclusive employment opportunity to capable, young graduates.

Manipal Education has several strategic investments in emerging companies, including - MeritTrac, India’s Largest Skills Assessment & Testing Company – a pioneer in this space in India, TutorVista, a leading online tutoring company and U21 Global, the world's premier online graduate school.

Manipal Education recently signed Anil Kumble, a leading international cricketer and the Captain of the Indian Cricket Team, as its Brand Ambassador. His academic and extra curricular achievements are mirrored in the values and vision of Manipal Education.

Dr. Pollak, a Ph.D. in Chemistry from the Swiss Federal Institute of Technology, Zurich, is internationally recognized as a pioneer in the development of the modern fine chemicals industry. He brings with him over 30 years experience in fine chemicals.

Commenting on the development, Mr. Jai Hiremath, Vice Chairman and Managing Director, Hikal Ltd. said, “Dr. Pollak is a worldwide authority in the field of fine chemicals. His global experience and expertise will be immensely beneficial to Hikal in the coming years.”

He worked for Lonza in Switzerland and the United States for more than thirty years in senior management positions with some outstanding achievements to his credit. Currently working as a consultant for the fine chemicals industry, Dr. Pollak has had several publications to his name including various articles in prestigious chemical magazines. Most recently he has published a book, Fine Chemicals: The Industry and the Business, Wiley, New York 2007.

Dr. Pollak said, “Hikal is recognized internationally as one of India’s leading contract manufacturers of fine chemicals. The recent signature of important manufacturing agreements with leading US and European lifescience companies demonstrates the value of its superior managerial and technological capabilities. I am happy to become part of the growth story.”

Hikal also has an Independent Scientific Advisory board consisting of Prof. Andrea Vasella from Switzerland, Prof. Govardhan Mehta and Dr. K. Nagarajan who are globally recognized experts in the field of fine chemicals.

Source: Press release distribution via India PRwire

About Hikal Ltd.:

Hikal is a reliable long-term outsourcing partner to companies in the Pharmaceuticals, Crop Protection Products, and Specialty Chemicals industry. The company has been supplying key active ingredients (AI) and intermediates, manufactured using stringent global quality standards, for it’s customers in the United States, Europe and Japan. Hikal’s advanced manufacturing facilities have been inspected and approved by leading global players in Crop protection and Pharmaceutical sectors. The crop protection facilities are located at Taloja and Mahad (Maharashtra). Hikal’s manufacturing activities are supported by state-of-the-art research centers and pilot plant facilities located at Bangalore and Taloja respectively. The API and pharmaceutical intermediates manufacturing facilities are situated in Jigani (Bangalore) and Panoli (Gujarat) respectively.

· The net sales are up by 63% to Rs. 91.9 crore compared to net sales of Rs. 56.2 crore in the corresponding quarter of the last year.

· PAT has risen by 23% to Rs 10.7 crore from Rs.8.7 crore the same quarter last year even after providing for Rs. 5.03 crore for foreign currency fluctuations.

· Registering an impressive growth of 145%, the pharma sales have risen to Rs. 60.1 crore in the first quarter of 2008 as against Rs. 24.5 crore in the previous year.

· The EBIDTA for this quarter stood at Rs. 24.8 crore, an increase of 36.2% as compared to Rs 18.2 crore in the corresponding quarter of the previous year.

Commenting on the results, Mr. Jai Hiremath, Vice Chairman & Managing Director of Hikal Ltd., said, “The long-term contracts signed earlier with leading global life sciences companies is now resulting in increased pharma sales. We expect this trend to continue as a number of our projects will go on stream in the coming quarters.”

Earlier this month, IFC, a member of the World Bank group, agreed to invest US$ 15 million in Hikal by way of equity. Hikal also announced the inauguration of a new multi-purpose agrochemical plant at Taloja for supply of Active Ingredients for Crop Protection Products to Bayer CropScience AG.

Source: Press release distribution via India PRwire

About Hikal:

Hikal is a reliable long-term outsourcing partner to companies in the Pharmaceuticals, Crop Protection Products, and Specialty Chemicals industry. The company has been supplying key active ingredients (AI) and intermediates, manufactured using stringent global quality standards, for it’s customers in the United States, Europe and Japan. Hikal’s advanced manufacturing facilities have been inspected and approved by leading global players in Crop protection and Pharmaceutical sectors. The crop protection facilities are located at Taloja and Mahad (Maharashtra). Hikal’s manufacturing activities are supported by state-of-the-art research centers and pilot plant facilities located at Bangalore and Taloja respectively. The API and pharmaceutical intermediates manufacturing facilities are situated in Jigani (Bangalore) and Panoli (Gujarat) respectively.

"So far Pune has been perceived as the hub for IT and auto industry but we have seen tremendous increase in response from job seekers in the Biotech and pharmacy sector. We have received about 1522 numbers of resumes for Biotech and medical research and about 633 numbers for Pharmaceutical and pharmacy job postings in the last three months", says Mr. Saurabh Shroff, Head Marketing, myjobsinPune.com

"In the last few months the number of biotech professionals posting resumes at myjobsinpiune.com has increased by roughly 30 percent", Mr. Shroff added further. With biotechnology industry registering over 35 percent growth in the last few years, this industry is seen as one of the key attributes that will contribute to the socio-economic growth of the state.

Companies like Emcure pharmaceuticals, Shreya Biotech and Lupin have set up their biotech parks and R&D centers of about 14 acres, 15 acres and 19 acres of area respectively in Pune. Also Mumbai based Hikal Ltd. has invested about Rs. 30 crores in its facility at the Pune Biotech Park. Apart from this MIDC & The Chatterjee Group (TCG) in a joint venture has developed, promoted and marketed the International Hinjewadi Biotech Park, in Pune.

The revenue from the biotech industry has been increasing steadily. The revenue has gone up to Rs 8541 crore during 2006-07 from Rs 4745 crore during 2004-05. The allocation for Biotechnology had been hiked to Rs 6500 crore for the eleventh plan period from Rs 621 crore during the ninth plan.

The biotechnology is a fast emerging sector and will play a key role in the new economy. Pune is well known for its established IT sector and with more and more pharma companies targeting Pune as their base for biotech parks.

According to an industry report, the city has gained attention from the government and the industry in attempt to provide conducive environment to foster biotech development. The government is trying to boost the sector by providing sector-specific promotion policy and requisite infrastructure in terms of various biotech parks and SEZs that are coming up in these cities.

Source: Press release distribution via India PRwire

"These conditions have many times led to problems in the foot and leg of diabetics," Dr S Lakshmi, Head of Department - preventive foot care, Dr A Ramachandran's Diabetes Hospital told reporters .

Speaking on the occasion of the launch of 'Crocs Rx' shoes for diabetics by multinational footwear company Crocs Inc., she said these shoes are made out of a special clog, helping prevent wounds in the foot and aiding diabetics in living a pain free life.

A clinical study of these shoes by Indian doctors on 100 patients had demonstrated that there was reduced pressure on the plantar aspect of the foot as compared with the pressure while wearing standard footwear, she said.

The Crocs Rx shoes also help heal skin infections, wounds and ulcers, she said.

The Crocs shoes will be available in leading hospitals and medical shops.

Source: Press release distribution via India PRwire

Crocs, is one of the famous footwear brands of US. Launched as a beach shoe in US, in 2002, it became famous as a lifestyle footwear brand.

Last year, Crocs launched its shoe range in India through its retail chain under the banner of Crocs India. Till date, this retail chain has placed products in more than 500 stores across India & also selling through the company owned stores in Metros like, Delhi, Mumbai, Pune and Gurgaon.

For more details, please visit. www.crocsindia.com

Alternatively call toll free number 18004256243 or 080-41474392 /93 for one on one counseling

Manipal College of Medical Sciences (MCOMS), Nepal was established in 1994. The institute is a result of collaboration between Manipal Group and the Government of Nepal. Located in Pokhara, a scenic location 200 km west of Kathmandu, MCOMS is affiliated to the Kathmandu University and is recognized across the world, for its high standards of excellence. MCOMS provides a five and a half years MBBS degree course (4 ½ years plus 1 year Internship) and postgraduate courses in all the basic science subjects and selected clinical subjects. MCOMS Nepal has students joining from India, SriLanka, Maldives, Bangladesh, Bhutan, Singapore, Middle East, Kenya, Australia, New Zealand, United States, Canada, United Kingdom and South Africa hence provides the student community a rich multi cultural exposure.

The four and a half years of the MBBS course is divided into nine semesters, each, six months in duration. On successful completion of the 4 ½ year MBBS degree course the student has to undergo one year of compulsory residential, rotating internship. The MBBS degree of MCOMS has been a recognized medical qualification in India since July 1999 vide Government of India gazette notification dated 26/9/2001 {V.11016/1/2000-ME(UG)}. However, vide gazette notification of 2002 all foreign medical graduates will have to clear the screening test in order to practice upon their return to India.

Rated the best college in Nepal nestled in the scenic, mountainous terrain of Pokhara, Manipal College of Medical Sciences (MCOMS) is an ideal centre of learning for medical students since 1994. An invigorating setting drawing inspiration from the lofty Himalayas, MCOMS is a modern campus with all conveniences, state of the art teaching aids and well equipped labs. MCOMS is also a cultural hub of activity as students from many different countries converge to take advantage of the exceptional faculty, holistic curriculum and innovative teaching methods.

MCOMS functions from two campuses. The Deep campus, spread on 8 acres of wooded land, houses the basic sciences departments, hostels and other facilities for Basic Sciences students. In the 30 acre Phulbari campus, is located the 700 Bed Manipal Teaching Hospital (MTH), clinical teaching departments, and hostels for clinical students. The quality of service provided is of an international standard. MTH has been constructed with a futuristic approach laying emphasis on the space required for teaching programs for undergraduates, postgraduates and allied health manpower.

Source: Press release distribution via India PRwire

About Manipal Education

Manipal Education is one of the largest education services providers from India. The group includes two universities, Manipal University & Sikkim Manipal University, and over 30 other institutions in India, besides colleges and university campuses in Antigua, Dubai, Malaysia and Nepal. Manipal Education currently has over 135,000 students from over 50 countries, of which about 25,000 students study at institutions and overseas campuses in India and abroad, while over 100,000 students undertake distance education, delivered using a blended approach including both satellite-based lectures and local coaching at 550 learning centres in India and overseas. Manipal Education also offers online testing and assessment for academic as well as corporate clients, and has recently launched professional education for service sectors like financial services, IT, media and retail.

Manipal Education recently partnered with ICICI a leading financial services group in establishing the ICICI Manipal Academy of Banking & Insurance. The academy is expected to expand the pool of industry ready resources and provide inclusive employment opportunity to capable, young graduates.

Manipal Education has several strategic investments in emerging companies, including - MeritTrac, India’s Largest Skills Assessment & Testing Company – a pioneer in this space in India, TutorVista, a leading online tutoring company and U21 Global, the world's premier online graduate school.

Manipal Education recently signed Anil Kumble, a leading international cricketer and the Captain of the Indian Cricket Team, as its Brand Ambassador. His academic and extra curricular achievements are mirrored in the values and vision of Manipal Education.

About MCOMS

An institution of the Manipal Education and Medical Group (MEMG), Nepal. MCOMS is affiliated to Kathmandu University, Dhulikhel, Nepal.

MCOMS has been accorded recognition by the Medical Councils of Nepal, Sri Lanka, Bangladesh, and Mauritius, besides the California Medical Boards & New York State Medical Board.

The college is listed in the 7th edition of the WHO’s world directory of accredited medical schools and the International Medical Education Directory of Educational Commission for Foreign Medical Graduates (ECFMG) which holds the United States Medical Licensing Exam. Manipal College of Medical Sciences (MCOMS) is also recognized by the British Columbia Student Assistance Program (BCSAP), Canada. Student loans and scholarships are also provided under the Manipal University loan scheme. The main vision of Manipal College

of Medical Sciences and Manipal Education is to be partners in the mission- “Health for All” and build a global leadership in human development, education and health care.

The equity will be offered to IFC by way of preferential share allotment which was approved at the meeting of Company’s Board of Directors held on July 3, 2008.

Mr. Jai Hiremath, Vice Chairman & Managing Director of Hikal Ltd., said, “The IFC investment clearly demonstrates the strength and potential of Hikal. Building long term strategic partnerships is the fundamental basis on which Hikal operates and we welcome IFC’s financial support as part of our growth strategy. The significant capital inflows will be used for capacity expansion across our manufacturing and R&D facilities.”

The expansions will be carried out at Hikal’s existing sites at Jigani (near Bangalore), Panoli (Gujarat) and Taloja (near Mumbai).

Earlier this week, Hikal announced the inauguration of a new Multipurpose Agrochemical plant at Taloja for supply of Active Ingredients for Crop Protection Products to Bayer CropScience AG.

Hikal also announced a final dividend of 70% for the year ended March 2008 (previous year 65%) subject to approval of the shareholders. This includes the interim dividend of 30% that was paid in February 2008 (previous year 30%). The Board of Directors has also approved the audited accounts for the financial year ended 31st March 2008.

Source: Press release distribution via India PRwire

About Hikal:

Hikal is a reliable long-term outsourcing partner to companies in the Pharmaceuticals, Crop Protection Products, and Specialty Chemicals industry. The company has been supplying key active ingredients (AI) and intermediates, manufactured using stringent global quality standards, for it’s customers in the United States, Europe and Japan. Hikal’s advanced manufacturing facilities have been inspected and approved by leading global players in Crop protection and Pharmaceutical sectors. The crop protection facilities are located at Taloja and Mahad (Maharashtra). Hikal’s manufacturing activities are supported by state-of-the-art research centers and pilot plant facilities located at Bangalore and Taloja respectively. The API and pharmaceutical intermediates manufacturing facilities are situated in Jigani (Bangalore) and Panoli (Gujarat) respectively.

1. Bal Pharma Revenue grew by 18.6%
2. Profit After Tax (PAT) grew by 38%
3. PBT grew by 28%
4. Revenue from our overseas sales grew by 15%
5. International foray for Ayurvedic products
6. Increased market presence for Branded formulations
7. Relaunched Generic division
8. New manufacturing plant at Uttaranchal is nearing completion and confirms to USFDA and MCHRA guidelines.
9. Received approval from Therapeutic Goods Administration (TGA), Australia for their API plant at Bommasandra, Bangalore.

Commenting on the results Mr. Shailesh Siroya, Managing Director, Bal Pharma limited said, “The growth in our revenues is a validation of our commitment to reach out to the rural masses with the quality and affordable medicines. Overall we have performed very well and are in line with our goals for the coming years. Bal Pharma achieved a turnover of Rs.90.35 Crore against our achievement of Rs. 76 crore for last year. We are now looking at an exponential growth and focus on achieving a turnover of Rs.300 Crore by the end of the year 2010, almost a fourfold growth by focusing on the Branded Formulations.

At the International level the company is planning to file more DMFs in different countries in next few months, and this would comprise of a basket of products being required by the various market as the company focuses on an advanced healthcare system and demand for all types of pharmaceuticals is high. We have done well to foray into foreign shores and have been successful in making an impact

Source: Press release distribution via India PRwire

ABOUT BAL PHARMA

Bal Pharma Ltd is a leading manufacturer, marketer and exporter of pharmaceutical products in India and abroad. Established in 1993, the company has an envious track record of providing its immaculate services in the health care market. The company’s strength spans a range of Branded formulations, APIs, Generics including Parentereals, and Intermediates, to Herbals. Bal Pharma has three manufacturing units, one for APIs coupled with R & D, the second for formulations both located at Bangalore and a third unit for Parentereals at Pune; all equipped with ultramodern state-of-the-art technology. All units conform to the GMP standards as laid down by WHO. Bal Pharma is one of the top companies in the country having the latest Form Fill and Seal (FFS) technology. With manpower of more than 1000 in the company, the company is committed to develop, manufacture and market innovative Pharma products. The company is presently targeting a four-fold growth to touch a turnover of Rs 300 crore by the end of 2010, by focusing on international markets and branded formulations.

Itero and Biological E. will collaborate to obtain worldwide approvals and commercialize jointly developed biopharmaceuticals. Itero will be responsible for financing the development of the drug candidates, while Biological E. will be responsible for financing the manufacture of the products to meet worldwide demand. Itero will retain commercial rights in the United States, Europe, and Japan, while Biological E. will retain commercial rights in all other territories.

"After a worldwide search of potential partners, we are thrilled to be collaborating with Biological E.," stated Bryan Lawlis, Ph.D., Chief Executive Officer of Itero. "Their expertise in biologics manufacturing and commercialization is demonstrated by their success in the Indian market and their collaborations with global pharmaceutical companies. Moreover we have the great advantage of working with a group of accomplished investors who have deep biologics operational experience in both the United States and India. Together, we believe that we can build a significant company focused on the cost-effective, worldwide development, production and commercialization of value-added protein and antibody-based therapeutics addressed to significant market opportunities."

"As Biological E. expands into a global player in the biopharmaceuticals industry, we are excited to be collaborating with Itero to jointly develop and manufacture important biotherapeutic products," noted Ray Prasad, Ph.D., Chief Operating Officer, Global Biologics of Biological E. "We look forward to working closely with the Itero team to establish cGMP certification and product approvals from the US FDA and EMEA for our biopharmaceuticals facilities."

Itero simultaneously announced that it has secured a $21 million Series A venture financing commitment. SV Life Sciences, the company’s largest shareholder, and Panorama Capital led the financing with additional participation from VenturEast. The proceeds will be used to fund the initial development of Itero’s therapeutic protein pipeline.

"We are excited to play a role in the formation of Itero," commented Michael Ross Ph.D., Managing Partner of SV Life Sciences. "Between the management team’s expertise in the development and commercialization of therapeutic proteins and their collaboration with their new Indian partner, we believe Itero is well-positioned to develop a deep biopharmaceutical pipeline while minimizing development risk and capital investment requirements for manufacturing."

"Panorama is pleased to back Itero and its experienced management team as one of the first life sciences investments out of our inaugural fund," said Srinivas Akkaraju, M.D., Ph.D., Managing Director of Panorama Capital. "Proteins and antibodies are a mainstay in medicine, and Itero’s unique collaboration with Biological E. may redefine how these important therapies are developed."

Bobba Venkatadri, General Partner from VenturEast commented, "We are pleased to be participating in Itero’s Series A financing. VenturEast has a long history of investing in early stage opportunities in India, and we look forward to supporting Itero’s management team with the experience base that we have established."

Itero said that as part of the financing, Drs. Akkaraju and Ross, as well as Mr. Venkatadri and Rodney Ferguson, J.D., Ph.D., Managing Director of Panorama Capital, had joined the Itero board of directors. Charles Harwood, a director of BioReliance Corporation and other healthcare companies, serves as an independent director.

Source: Press release distribution via India PRwire

About Itero
Itero Biopharmaceuticals, a San Mateo, CA based biopharmaceutical company, is focused on developing value-added follow-on and novel therapeutic proteins and antibodies. The company was founded in early 2007 by a group of experienced biotechnology industry executives, including:

·V. Bryan Lawlis, Ph.D., Chief Executive Officer and a director, formerly CEO of Covance Biotechnology Services and Aradigm Corporation and VP, Process Development of Genentech, Inc.;
·R. Jerald Beers, SVP and Chief Commercial Officer, formerly EVP, Business Development and Marketing of Aradigm, General Manager of Genentech Canada, Inc. and VP, Marketing of Genentech, Inc.;
·Darlene Horton, M.D., SVP and Chief Medical Officer, formerly SVP of Clinical Research and Medical Affairs at Scios, Inc. (J&J), Head of Cardiovascular Clinical Development at J&J and a Pediatric Cardiologist;
·Mark Olbert, SVP and Chief Financial Officer, formerly VP, Finance and Chief Financial Officer of Aradigm.

Itero leverages its expertise in biotechnology and its manufacturing collaboration with Biological E., Hyderabad, India, to efficiently and cost-effectively develop therapeutic proteins and antibodies. The company will initially develop differentiated follow-on proteins, addressing certain segments of the greater than $25 billion market for biopharmaceuticals coming off patent in the near term. The company will also leverage its development and commercialization expertise and manufacturing capability to partner with developers of novel biopharmaceuticals. For more information, please visit the company’s website at http://www.iterobiopharm.com.

About Biological E.
Established in 1953, Biological E. Ltd. (BE) has been a leading vaccine and pharmaceutical company based out of Hyderabad, India. The company produces a range of critical vaccines and has been an active partner with the National Immunization Programs of various countries. The company continues to invest in large-scale cGMP facilities in order to increase its capacities and product range to offer vaccines/biologics on a global basis including US FDA and EMEA markets. In addition to its pipeline of vaccines and biologics, the company has entered into a number of strategic collaborations with leading biotech companies and research institutes for joint R&D projects. Biological E. is a privately held company and is run by professionals with significant experience in the global biopharmaceutical business. For more information, please visit the company’s website at http://www.biologicale.com.

About Panorama Capital
Panorama Capital is a venture capital firm focused on technology and life sciences companies. Panorama Capital has a singular focus: helping entrepreneurs build market-leading companies. Panorama invests in entrepreneurs and teams who share its values: a passion to build great companies; an unyielding focus on people and teamwork; and a commitment to integrity. Panorama’s philosophy is to make that same commitment to the teams it supports, over and above its financial investment, and to take a hands-on, highly collaborative approach to investing, bringing to each portfolio company the team’s extensive operating and investing experience. For more information, please visit the company’s website at http://www.panoramacapital.com.

About SV Life Sciences
SV Life Sciences Advisers, LLC (“SVLS”) is a life sciences-focused venture capital business. SVLS funds invest in companies requiring funding within the human life sciences sector including biotechnology and pharmaceuticals, medical devices and instruments, healthcare IT and services. SVLS advises or manages four venture capital funds and a publicly traded investment trust with total capital of approximately $1.6 billion that invest in life sciences companies at all stages of development. SVLS has 29 professionals and has invested in over 175 companies over the course of the last decade making SVLS one of the largest and most active healthcare investors in the world. SVLS was established in 1993 and currently has offices in Boston, San Francisco and London. For more information, please visit the company’s website at http://www.svlsa.com.

About VenturEast
VenturEast’s Biotechnology Fund is the only early-stage life sciences focused venture fund in India. The fund management team, including Sarath Naru, Shekhar Reddy, Ramesh Alur and Bobba Venkatadri, is one of the oldest operating VC teams in the country. The management team, with strong operating background, has built quite a few market leaders and built a reputation as a preferred early stage VC investor in India. VenturEast works closely with its entrepreneurs and helps them develop business plans to build unique competitive advantages. The fund has invested in pioneering cross-border drug discovery deals where Indian operations of US and European companies are providing cost-efficient R&D in biology and chemistry; and scaled manufacturing for biologics. Itero is a classic example of our modus operandi where we have helped the company to identify products and partners in India. The fund has also invested in India-specific opportunities in healthcare services and clean technology adoption. For more information, please visit the company’s website at http://www.ventureast.net.

Committed to offer the latest in cancer therapy in India and world wide, the oncology division will manufacture and market the products at an affordable cost. The facility is designed to comply with the requirements of global regulatory authorities.

The facility is based on the latest isolation technology that will ensure protection of the products, operating personnel and environment.

The Company also inaugurated its subsidiary Gennova Biopharmaceuticals’ Malaria Vaccine Facility that will develop and manufacture malaria vaccine candidates for worldwide clinical trials. Gennova is also located at Hinjwadi, Pune.

The new facilities were inaugurated at the hands of Shri. Sharad Pawar, Honorable Minister for Agriculture, Government of India.

“The oncology market in India is estimated at Rs. 400 crores and is growing at the rate of 30%. We aim to achieve 15-20% market share in this segment within next 5 years,” said Mr. Satish Mehta, CEO, Emcure Pharmaceuticals Ltd.

Mr. Arun Khanna, COO, Emcure Pharmaceuticals Ltd said, “In India, patients have limited access to the latest cancer therapy. We will offer a vertically integrated solution for cytotoxic drug substance and drug product manufactured at our facilities at an affordable price”

Over 12 million people are diagnosed with cancer each year. As per WHO, India has an estimated seven lakh new cases added every year.

Source: Press release distribution via India PRwire

About Emcure:

Established in 1983, Emcure was born out of the vision to create a healthcare company that would address the vast healthcare needs. The company’s commitment and drive have propelled its growth from a single manufacturing facility at the genesis, to a range of world class research and manufacturing facilities spread across API, formulations and biotechnology.

Headquartered in Pune, India, Emcure is today a vertically integrated pharmaceutical company with infrastructure, skills and resources that are at par with the best in the world. The Company has carved a niche for itself as a preferred outsourcing partner for some of the largest MNCs both in the Indian and global markets.

Emcure also researches, manufactures and markets formulations under its own brands in the domestic market and exports formulations to over 60 countries across USA, Europe, Asia, Africa, CIS, Latin America and the Middle East. Emcure’s pioneer chiral product S-Amlodipine is marketed in 31 countries worldwide.

About Gennova Biopharmaceuticals:

Gennova Biopharmaceuticals Ltd (GBL), is a biotech company located in Pune, India. GBL is a subsidiary of Emcure Pharmaceuticals Ltd. GBL already manufactures and markets its own brands of TNK-tPA (Tissue-Plasminogen Activator), GM-CSF (Granulocyte-Macrophage Colony Stimulating Factor) and EPO (recombinant human erythropoietin) and boasts of a robust pipeline. GBL has well established recombinant protein expression and characterization platforms using E. coli, yeast, and mammalian (CHO cells) systems.

The Company proposes to utilise the net proceeds of the Issue to part finance its Rs 5500 lacs expansion plan. The plan cover expansion of existing facilities and establishment of new centers with latest technology. To fund this plan, Lotus expects to raise Rs 4200 lacs through the public issue, it has tied up Rs 999.54 lacs of term loans from banks and raises remaining Rs 300.46 lacs through internal accruals.

Lotus plans to strengthen its presence in southern part of India by providing three fold services in eye care industry. It proposes to set up 2 Primary Eye Care units in Bangalore and 1 unit in Chennai with focus on diagnosis and dispensation of simple eye problems and optical sales. Further, Secondary Eye Care centers will be opened at R.S. Puram, Tirupur and Karur and a Tertiary Eye Care center at Salem. It has already bought land at R.S.Puram on which work of construction is in process. The construction at Peelamedu and R.S.Puram has already been commenced. The construction of hospital at Tirupur, Salem and Karur will be commenced after acquisition of suitable land. The Company also intends to set up more eye care centers in different parts of the country.

Lotus Eye Care Hospital Ltd, promoted by renowned eye surgeon Dr. S.K.Sundaramurthy, at present has a network of four eye care hospitals based at Coimbatore (2), Salem (1) and Tirupur (1). These hospitals have hitec eye care equipments and ophthalmic experts backed by well-trained paramedical and administrative team. All the centers have fully computerized modern setup manned by medical and administrative staff. The network of eye care hospitals has 9 operation theatres and 3 lasik laser equipments and total bed strength of all the centers is 120 beds excluding eye camp beds.

In 1998 Lotus introduced Multi Scan Lasik and in 2002 Wave front based Esiris Custom Lasik for the first time in India. Lotus was the first Eye hospital in South East Asia to have Epilasik in July 2004. In June 2005 Lotus introduced the most advanced technology of Zyoptix and combined two superior technologies Epilasik and Zyoptix known as Zyoptix Integrated Epilasik to achieve supervision. During the calendar year 2007, they performed over 4200 nos of various surgeries as cataract, Lasik/Epilasik, corneal, vitreo-retinal, squint, oculoplastic and orbital. All imported hi-end surgical equipments with latest laser technology is used in all the units.

The sources of income for the Company are from outpatient, daycare and inpatient hospital services and retail sales in the pharmacy and opticals. During 2006-2007, the Company reported a net profit of Rs.128.67 lacs on total income of Rs.729.90 lacs. During the nine months period ended 31st December 2007 it reported a net profit of Rs.158.79 lacs on total income of Rs. 897.27 lacs.

Lotus is affiliated to National Board of Examination (NBE) a government body for post-graduate training in ophthalmology. Lotus group has been authorized to educate and train 4 candidates in a year for post-graduate ophthalmology. Lotus also offers fellowship-training programme for fresh and practicing ophthalmology in cataract with IOL surgery, Lasik/Epilasik surgery, vitro-retinal surgery, Pediatric ophthalmology and corneal surgery. An optometry institute affiliated to Dr.Alagappa University, Karaikudy is run by group concern LVRT for courses in Bsc.(Optometry) and Diploma in Ophthalmic Technologies.

Lotus had conducted International ophthalmic conference in Sea Cruise, a Luxury Liner which started its journey from Mumbai and went to Lakshadeep via Goa. The conference was attended by internationally reputed Opthalmic surgeons for a period of 5 days. It was the first time the medical conference was held on sea. For that the name of Lotus has entered into Limca book of records.

Disclaimer

Lotus Eye Care Hospital Ltd is proposing, subject to market conditions and other considerations, a public issue of the equity shares and has filed the Red Herring Prospectus with Registrar of Companies (ROC), Chennai. The Red Herring Prospectus will be available on the website of SEBI at www.sebi.gov.in, the website of the Book Running Lead Manager at www.keynoteindia.net, and the website of the Company at www.lotuseye.org.

This press release does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any equity shares, nor shall it or any part of it nor the fact of its distribution form the basis of, or be relied on in connection with, any contract or investment decision.

The Equity Shares have not been and will not be registered under the US Securities Act (“the Securities Act”) or any state securities laws in the United States and may not be issued or sold within the United States or to, or for the account or benefit of, “U.S. persons” (as defined in Regulation S under the Securities Act), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act.

Any potential investor should note that investment in equity shares involves a high degree of risk. For details, see the section titled “Risk Factors” of the Red Herring Prospectus, which has been filed with the Registrar of Companies.

Source: Press release distribution via India PRwire

About Lotus Eye Care Hospitals:

Located in Coimbatore, Salem and Tirupur, Lotus Eye Care Hospitals are one of the leading eye care hospitals in south India. They not only provide treatment for various eye diseases, but also offer comprehensive preventive measures and educational programs.

Offering comprehensive tertiary eye care and manned by specialist ophthalmic consultants, Lotus Hospitals meet international standards in eye care. Over the last 15 years, Lotus has become a trusted name in eye care and thousands of patients have benefited from it.

Lotus has been the pioneer in inducting latest world-class technologies into our country. Multi scan Lasik, Epilasik, Zyoptix Z100 are some of the technologies introduced by Lotus. Their hospitals are equipped with ultra modern fourth generation instruments, required for critical ophthalmic surgeries.

Many elderly people, specially Diabetics, who experience leg pain when they walk, pain or numbness in the legs or feet, or cramps and muscle fatigue in the legs, may be suffering from peripheral vascular disease (PVD) or lower leg PVD, a common, but under diagnosed condition affecting millions of people and a major cause of stroke and heart attacks.

Speaking on the occasion Dr Shirish (M.S) Hiremath, Director, Dept of Cardiology & Endovascular Intervention, Ruby Hall, Pune, said, “Lower leg PVD is a common syndrome that affects a large proportion of most adult populations worldwide, with a prevalence over 10% in people aged more than 40 years and increasingly so in patients with associated risk factors like Coronary Artery Disease, Smoker, Diabetics”.

Fortunately for patients with lower leg PVD, the disease, if detected and treated early, could usually be resolved.

Dr Dhanesh Kamerkar, Vascular Surgeon, RubyHall, Pune was of the opinion that, “The more people know about the disease, the greater the chances are of preventing disability and serious consequence.”

Unfortunately, many people with the early symptoms of lower leg PVD, especially leg pain on walking, assume that this is just part of getting older and do not seek medical attention until they become severely debilitated.

Thus, this Interactive Session and Awareness Program was to bring to the notice of the common man that sometimes even the most ordinary ailments and pains could lead to life threatening and the most complicated disorders, as also to inform them that all their big and minor pains and illness need to be checked up and not to be ignored.

Source: Press release distribution via India PRwire

Mark Loughead, Chief Operating Officer,Intertek Group plc, commented:

“India is an important and fast expanding economy and a priority country in the global market for Intertek.

I am pleased to announce the appointment of Harsh Chopra as Country Manager for India.

Harsh, a Chemical Engineer from ITBHU, has a diverse background in consumer goods, health care, fashion and luxury and functional experience spanning Technical, Quality, Supply Chain and Sales & Marketing. Harsh will drive growth through acquisitions and accelerated organic growth by leveraging synergies across divisions.

Harsh was most recently the Managing Director of RayBan Sun Optics India and prior to that worked for Bausch & Lomb and Hindustan Unilever.

Anil Kumar, Non-Executive Chairman of Intertek India commented “ I welcome Harsh to this important role in the Group in India and we believe that with the focus on leveraging synergies across divisions we will be able to provide seamless service to our customers across business divisions”.

Intertek has 4 Divisions in India – Consumer Goods lead by Dilip Gianchandani, Oil, Chemicals & Agri by Rajaram Kalpathi, Commertial & Electrical and Systems Certification by Rajesh Saigal and Government Services by Sridhar Raghavan.

Source: Press release distribution via India PRwire

About Intertek India

Intertek offers Services in India which include quality control, laboratory testing, inspection, systems certification, safety marks and auditing for a wide range of industries, markets and institutions. Intertek India services provide the world-class experience, expertise, resources and capabilities required to support customers through a international network of Indian and international laboratories and offices.

Examples of industries serviced by Intertek in India include electronics, chemicals, textiles, petroleum, minerals, consumer goods, agricultural products, food, pharmaceuticals and much more.

From auditing and inspection, to testing, quality assurance and certification, Intertek people are dedicated to adding value to customers' products and processes, supporting their success in the global marketplace. Internationally, Intertek has the expertise, resources and global reach to support its customers through its network of more than 1,000 laboratories and offices and over 21,000 people in 110 countries around the world. For more information, visit www.intertek.com

The Minister of Health and Family Welfare, Dr. Anbumani Ramadoss has said that the enterprises were ordered to suspend production for non-compliance with good manufacturing practice (GMP). This gives rise to many issues:

1) Since the public enterprises were under the Ministry of Health and Family Welfare, what did the Minister of Health and Family Welfare, do over the past 4 years to ensure their compliance with newer norms? While the Government is planning to spend Rs. 300–500 crores to develop the upcoming vaccine and medical park in Chengalpattu which will become operational in 2012, why were these three enterprises which were engaged in vaccine production since decades not provided with the Rs. 50-60 crores they required? Who will supply vaccines in the interim, and at what cost?

2) The closure of vaccine production in these units comes at a time, when the demand-supply in vaccines for India’s Expanded Program for Immunization (EPI) is widening and coverage of immunization against these crucial vaccine preventable diseases is declining. The closure of production of these vaccines, will have enormous implications for the cost and access to these vaccines in the future.

In this context, the allegations of purchase of raw material for measles vaccines at inflated cost from private companies, providing them raw material from these 3 units at either free or at ridiculously low prices, and further agreeing to profit-sharing needs an enquiry at the highest level. The Government must reverse with immediate effect its directives on the functioning of these enterprises and ensure all assistance to make them compliant with newer norms.

Source: Press release distribution via India PRwire

“India is an important and fast expanding economy and a priority country in the global market for Intertek.

I am pleased to announce the appointment of Harsh Chopra as Country Manager for India.

Harsh, a Chemical Engineer from ITBHU, has a diverse background in consumer goods, health care, fashion and luxury and functional experience spanning Technical, Quality, Supply Chain and Sales & Marketing. Harsh will drive growth through acquisitions and accelerated organic growth by leveraging synergies across divisions.

Harsh was most recently the Managing Director of RayBan Sun Optics India and prior to that worked for Bausch & Lomb and Hindustan Unilever.

Anil Kumar, Non-Executive Chairman of Intertek India commented “ I welcome Harsh to this important role in the Group in India and we believe that with the focus on leveraging synergies across divisions we will be able to provide seamless service to our customers across business divisions”.

Intertek has 4 Divisions in India – Consumer Goods lead by Dilip Gianchandani, Oil, Chemicals & Agri by Rajaram Kalpathi, Commertial & Electrical and Systems Certification by Rajesh Saigal and Government Services by Sridhar Raghavan.

Source: Press release distribution via India PRwire

About Intertek India

Intertek offers Services in India which include quality control, laboratory testing, inspection, systems certification, safety marks and auditing for a wide range of industries, markets and institutions. Intertek India services provide the world-class experience, expertise, resources and capabilities required to support customers through a international network of Indian and international laboratories and offices.

Examples of industries serviced by Intertek in India include electronics, chemicals, textiles, petroleum, minerals, consumer goods, agricultural products, food, pharmaceuticals and much more.

From auditing and inspection, to testing, quality assurance and certification, Intertek people are dedicated to adding value to customers' products and processes, supporting their success in the global marketplace. Internationally, Intertek has the expertise, resources and global reach to support its customers through its network of more than 1,000 laboratories and offices and over 21,000 people in 110 countries around the world. For more information, visit www.intertek.com

Dr. B.C. Roy National Award has been instituted to recognize the best talents in encouraging the development of specialties in different branches of Medicine. The value of each award is Rs.15, 000/- and a Medal which given in a special investiture ceremony by The President of India.

Speaking on the occasion, Dr, Dang said “the Award is a recognition of his efforts that have gone into development of specialty of laboratory medicine which was for very long been considered behind the scene. But now it is a front-runner amongst other core specialties. Indian Laboratory Medicine is now at par with international standards”.

Dr. Dang began his career at AIIMS in 1982 after completing his MBBS from UCMS, Delhi University. He further went on to do his MD in medical microbiology from PGIMER Chandigarh. Prior to setting up Dr. Dang’s Laboratories Dr. Dang was with Ranbaxy Laboratories.

Bagging the Award comes as great news for Dr. Dang as he plans to expand the range of Lab tests to include more tests in molecular biology, immunology, and infectious diseases. Dr. Dang’s Medical Diagnostic Center’s core forte is to focus of quality control and quality management to provide the best and cost effective options to its patients.

Source: Press release distribution via India PRwire

About Dr. Dang’s Medical Diagnostic Center:

Dr. Dang’s Medical Diagnostic Centre was started in 1983 and became the first private pathology laboratory in the country. Dr. Dang’s Lab is run Jointly with Dr Manju Dang who is a specialist in Pathology. The Lab provides a wide range of tests and believes in putting patients’ first. Dr. Dang’s Lab is one of the first Labs in the country to receive the ISO 9002 certification and accreditation from NABL: National Accreditation Board For Testing And Calibration Laboratories under Department of Science and Technology Government of India.

For more Information please contact: Priyanka Bhattacharji @9811698914

Similarly, to fulfill the needs of the Pharma Industry with particular reference to skilled manpower in areas like Analytical, Quality Control, Pharm Microbiology and Bioinformatics, SPTM has launched a Two Year Full Time M.Sc. Program in Applied Pharm Analysis / Applied Pharm Bioinformatics and Applied Pharm Microbiology.

Details of the programs are as below:

(1)

One Year Full Time P G Diploma in Drug Regulatory Affairs (PGDRA) And

P G Diploma in Pharmaceutical Marketing (PGDPM)

Objective: Considering the growth in the pharmaceutical industries at international level, Drug regulatory activities are being prioritized to cater to the needs of pharma global competition. India as a developing country has to look into HR expertise to address the issues related to drug laws and guidelines of regulatory agencies of various countries. Currently there is no such attempt to cater to the need of pharma industries.

Eligibility: B.Pharm./ M.Pharm. with a minimum 55% marks.

Selection Procedure: Based on performance in Admission Test and Personal Interview to be held at NMIMS, Mumbai

Application Procedure: Applications forms are available and can be acquired from the Accounts Office NMIMS, Mumbai on payment of Rs. 950/- (non – refundable) in person or by sending a DD of Rs. 1050/- (non – refundable, inclusive of courier charges) favoring SVKM’s NMIMS, payable at Mumbai with a self addressed cloth envelope of size 10 “ X 13” .

Important Date

A) Start of issue of application forms - 8th May 2008.

B) Last date for issue of application form - 10th June 2008

C) Last date for receipt of application forms - 12th June 2008

D) Conduct of Admission Test 2008 at NMIMS, Mumbai - 22nd June 2008

E) Personal Interview at NMIMS University, Mumbai Campus - 22nd , 23rd & 24th June 2008

F) Admission on counseling basis as per merit at NMIMS Mumbai and payment of fees - 11th & 12th July 2008

G) Registration, Inaugural and Orientation - 30th & 31st July 2008

H) Commencement of regular classes -1st August 2008

Intake Capacity: 20 per specialization

Unique features of the programme: The programme will develop analytical mind, scientific thinking and skills required for drug regulatory affairs and pharma marketing. Case studies, interaction with experienced professionals and field/professional experience in the field shall be the strength of the curriculum

Programme structure: One year- Three trimesters out of which two trimesters by theory and one trimester by project work.

Please visit our website www.nmims.edu for more details or speak to our counselors on 022- 64521148/49/50

(2)

Two Year Full Time M.Sc Programme In Applied Pharm Analysis/ Applied Pharm Bioinformatics/ Applied Pharm Microbiology

School of Pharmacy & Technology Management (SPTM) of SVKM’s NMIMS University has designed a unique MSc programme with specialization in Applied Pharm Analysis/ Applied Pharm Bioinformatics /Applied Pharm Microbiology

Objective: This MSc programme has been prepared taking into consideration the needs of the Pharmaceutical industry with particular reference to skilled manpower in areas like Analytical, Quality Control, Pharm Microbiology and Bioinformatics. Currently the post graduate courses in Science stream face difficulty in placement and employability due to lack of Pharma industry specific skills.

Eligibility: B.Sc/M.Sc with Chemistry/Microbiology or Biotechnology (as a major subject) or B.Pharm with a minimum of 55% marks. Students with Pharmaceutical Industry experience shall be preferred

Selection Procedure: Based on performance in Admission Test 2008 and Personal Interview to be held in Mumbai

Application Procedure: Applications forms are available and can be acquired from the Accounts Office NMIMS, Mumbai on payment of Rs. 950/- (non – refundable) in person or by sending a DD of Rs. 1050/- (non – refundable, inclusive of courier charges) favoring SVKM’s NMIMS, payable at Mumbai with a self addressed cloth envelope of size 10 “ X 13” .

Important Dates

A) Start of issue of application forms - 8th May 2008.

B) Last date for issue of application form - 10th June 2008

C) Last date for receipt of application forms - 12th June 2008

D) Conduct of Admission Test 2008 at NMIMS, Mumbai - 22nd June 2008

E) Personal Interview at NMIMS University, Mumbai Campus - 22nd , 23rd & 24th June 2008

F) Admission on counseling basis as per merit at NMIMS Mumbai and payment of fees - 11th & 12th July 2008

G) Registration, Inaugural and Orientation - 30th & 31st July 2008

H) Commencement of regular classes -1st August 2008

Intake Capacity: 20 seats in each specialization for Applied Pharm Analysis/ Applied Pharm Bioinformatics/ Applied Pharm Microbiology

Pedagogy: The course will be predominantly based on practice and interaction with a strong focus on Pharma industry operations. It will equip the students to address the Pharma industry’s needs in a skilled manner.

Unique features of the Programme: The programme will inculcate technical attitude and skills required for Applied Pharm Analysis, Applied Pharm Bioinformatics and Applied Pharm Microbiology through electives and industrial project for thesis in the final semester. Case studies at all levels and hands on training with all the analytical tools shall be the strength of the curriculum.

Programme structure: Two Years. Three semesters by papers and one semester by project work/ dissertation in Industry

Please visit our website www.nmims.edu for more details or speak to our counselors on 022-64521148/49/50

Source: Press release distribution via India PRwire

About SVKM’s NMIMS University

Established in 1981, as a Management Institute, NMIMS has now transformed itself into a University, with 8 Schools, over 150 full-time faculty members, 42000 books and over 2500 students enrolling every year, transforming from an Institute of single management faculty to a University with many faculty areas. The University is also transforming from a Teaching Institute to Research-Consultancy-Training & Teaching Institute.

NMIMS has taken many new academic initiatives under various Schools like

• School of business Management
• Mukesh Patel School of technology Management & Engineering
• School of Pharmacy & Technology Management
• Balwant Sheth School of Architecture
• School of Commerce
• School of Science
• School of Distance Learning
• Institute of Intellectual Property Studies

Number of innovative Graduate, Post Graduate and Doctorate level programs, meeting the Industry/Business requirement under each school.

Achievements:

• Golden Pecock Award for innovation 2006 & 2007
• BMA Best Management Institute of the Year Award 2004-05 & 2006-07
• BMA Best teacher of Management of the Year Award 2004-05 & 2005-06
• Dr. J J Irani Award for Best Management Institute 2005
• Gurukuljyoti Award for Excellence in Education 2006
• The National Assessment and Accreditation Council (NAAC) has accredited an ‘A’ grade with a score between 85-90%.
• Ranked amongst top 10 B-School in Business Today- Nielsen Best B-School Survey 2007 and Outlook-C fore Best B-School Survey 2007
• Ranked amongst Super League B-School in AIMA-Indian Management Best B-School Survey 2007.

NMIMS also be launching Off-Campus Centres at Shirpur, Hyderabad, Bangluru soon.

For further details please visit www.nmims.edu

C-Pink is now amongst the top 300 ethical formulation brands in India and is ranked at 186th. It has moved from the 89th overall position to 61st position over the last 12 months as per ORG IMS data

“The revamp of the human resource and the persistent efforts to reduce costs has finally paid off in terms of growth and we are proud to have found our way to the top. And this is just the beginning.” said Mr. Ashok Shinkar, Director Corporate Finance, Wanbury Ltd.

As per ORG IMS data, Wanbury is the fastest growing domestic Pharmaceutical Company amongst the top 150 Pharma companies.

The product is well accepted by Gynecologists, Pediatricians and general physicians. An all India presence and sales marketing team of over 400 personnel has contributed to making this a strong brand.

Some other successes

Some of the other salient launches made by the Company include Rabiplus in the Gastro and Physician segment with sales of Rs. 20 cr p.a., Folinine in the Gynecology segment with annualized sales aggregating Rs. 6 crore and Adtrol Plus for the Orthopedic segment which shall also be clocking a sale in excess of Rs. 10 cr for the year.

The most recent launch of the Company this quarter is “Incyto”. This molecule has been launched in India for the first time and caters to Cardiology and Diabetic segment. The sales expected would be in excess of Rs. 10 cr for the first 12 months.

Thus average sales of all new brands launched by the Company is in excess of Rs. 10 cr which speaks well of the competency of the Company to launch and position new brands in the ethical pharmaceutical market.

The Company is planning to launch new molecules in the Gynecology and Physicians segments also aiming to improve the average brand size of Rs. 10cr.

The company plans some more launches in the coming year based on an in-depth study of the market aided by leading consultancy firms like IMS SDG to identify niche products for development. The Company has identified a number of Value Added Generic, Rational Finished Dosage Combination products and innovator products for In-Licensing.

The Company already has a strong presence in Gynecology, Orthopedics, Pediatrics and General Physicians. With these products, theCompany shall also enter other specialty areas and be a preferred partner for in-licensed products.

Source: Press release distribution via India PRwire

About Wanbury Ltd

Wanbury is the world’s largest producer of Metformin. It is the largest supplier of Metformin, Tramadol and Salsalate in the US markets. The company has diversified revenue streams that include API (mainly to the regulated market), sales of branded ethical formulations in India, and Spain, and sales from CRAMS business where it caters to some of the largest MNCs. The company is also an upcoming player in CRAMS with an expanded capacity of over 8500 tonnes.

Speaking on the development, mr. Mani Iyer, Executive Director, IBPL, said, “This business deal brings together two companies having respective expertise in niche areas of operations. IBPL and Apotex have complementary strengths, which will help in launching the first GCSF generic in North America. IBPL and Apotex are eying a significant share of total G-CSF market in North America and Europe, which is currently estimated to be around $1.4 billion annually. Although guidelines for biosimilar product registration in North America are not yet finalized, the companies anticipate that there would be a clear pathway for biotech companies, once the legislation is in place.

As far as IBPL is concerned, North America and Europe are ideal markets to serve the goal of developing innovative research technologies/new molecules related to biopharmaceuticals; evaluate technology platforms; identify partnership opportunities, in-licensable IPs; and to build up Novel Drug Delivery System. IBPL and Apotex are keen to explore prospective business opportunities for more biosimilar products in the coming years.”

Dr. Jeremy B Desai, Executive Vice President, Research & Development, Apotex adds “This agreement represents an important milestone for Apotex, as it strengthens the organization’s development in Europe and will offer support for entering this important market with future biosimilar products currently in the Apotex development pipeline”.

Dr. Helmut Brunar, VP Research and Business Development, Kwizda Pharma explains mutual benefits of the agreement: “It is part of Kwizda Pharma’s current business strategy to work together with non-European pharmaceutical companies to break into the European market. That is why we worked with IBPL to successfully complete a phase I clinical trial and have transferred our rights in IBPL’s G-CSF to Apotex including initiation of a phase III trial for the approval of G-CSF in Europe”.

Amongst top five leaders in generic market, Apotex has a strong registration, marketing & distribution team whereas IBPL offers a unique competitive advantage in terms of R&D and Manufacturing of biopharmaceuticals. The deal offers immense growth opportunities for both, Apotex and IBPL, as they look to consolidate their presence in the global biogenerics market. Neukine® (rHu GCSF) is the first drug introduced by IBPL in India and subsequently Erykine® (rHu EPO), Intalfa® (rHu IFN) and Neupeg™ (Peg GCSF) in domestic market and few international markets. IBPL has also entered into several distribution and marketing agreements with reputed international companies in regulated and semi-regulated markets of Europe, Asia-Pacific, Middle East, Russia & CIS, South and Central America and Africa.

Source: Press release distribution via India PRwire

About Intas Biopharmaceuticals Limited:

Since launch of biotechnology operations in May 2000, Research & Development, Manufacturing and Marketing of biopharmaceutical products, with a special focus on Oncology (Cancer), are major thrust areas for IBPL. The company is India’s first and only biopharmaceuticals manufacturing company to receive European Union – Good Manufacturing Practice (EU-GMP) certification. Today, Intas Biopharmaceuticals Limited is the sole manufacturer of Pegylated GCSF in India and markets under the brand name “NEUPEG”.

About Kwizda GmbH

Kwizda GmbH is a privately owned group of companies and has been operating since 1853 (pharmaceutical division). Kwizda Pharma is a leading Austrian manufacturer and wholesaler of proprietary, in-licensed and third-party pharmaceuticals, OTC drugs and hospital infusions. In 2007, the company recorded sales of approximately EUR 50 million.

About Apotex Inc.

Apotex Inc. is the largest Canadian-owned pharmaceutical company, employing over 6,800 people in research, development, manufacturing and distribution facilities world-wide. Apotex produces more than 300 generic molecules in a variety of different presentations, which, in Canada, are used to fill over 75 million prescriptions a year - the largest amount of any pharmaceutical company in this country. In the next 10 years, Apotex will spend $2 Billion in R&D and has presently over 600 products under development.

The advisory board is created to provide Bilcare GCS Management Team with independent scientific industry expertise and insight to assist in the accomplishment of scientific and business objectives.

Dr. LaMattina had a distinguished 30-year career at Pfizer, where he held various positions, including Senior Vice President of Pfizer Inc., and President of Pfizer Global Research and Development. In his role, Dr. LaMattina oversaw the drug discovery and development efforts of more than 12,000 colleagues in the United States, Europe and Asia. Dr. LaMattina is the author of 23 scientific publications and holds 15 U.S. patents. He is the 2004 recipient of the American Diabetes Association Award for Leadership and Commitment in the Fight Against Diabetes. Dr. LaMattina serves on the Board of Trustees of Boston College and the Board of Trustees of Worcester Polytechnic Institute. “I am honored to be on the Corporate Advisory Board of a company that is on the rise and gaining well-deserved recognition throughout the industry,” said LaMattina. “I am confident that the Advisory Board will play a pivotal role in the future success of Bilcare’s contribution to the Clinical Research Industry.”

Dr. Carty is the first Executive Director of the Waterloo Institute of Nanotechnology and the former National Science Advisor to Canada’s Prime Minister. A noted academic, Dr. Carty had a distinguished career as the President of the National Research Council of Canada from 1994 to 2004 after which he was appointed as the National Science Advisor. Prior to his recent return to the institute, Dr. Carty spent 27 years as a professor of chemistry at the University of Waterloo, serving as Chairman of the chemistry department and Dean of Research. He has authored more than 285 papers in referred journals and multiple book chapters and review articles, and also has five patents. Dr. Carty is a distinguished member of multiple boards including two for the Networks of Centres of Excellence and Genome Canada. Dr. Carty is both an Officer of the Order of Canada and Officer de L’Ordre National du Merite of France. “Serving on the corporate Advisory Board is an honor and comes with great responsibility,” said Carty. “I am committed to providing technology and biotech expertise to Bilcare GCS to further its business objectives.”

“We are honored to have Dr. LaMattina and Dr. Carty as an integral part of the Bilcare team and look forward to a long association with them and to their successful contribution especially in the areas of technology, research and innovation.” said Vito Mangiardi, CEO, GCS Bilcare.

Bilcare Global Clinical Supplies serves the Americas, Europe, and Asia with clinical trial materials support, services and complete project management. Our services for solid, semi-solid, liquid, DEA (CI-V) and biotech clinical trial materials (CTM) satisfy a broad range of requirements, from pre-

formulation research and development, analytical services and clinical supplies packaging and labeling, to IVRS, controlled temperature (cold and frozen chain) CTM storage, distribution worldwide, and returns and destructions accountability.

Source: Press release distribution via India PRwire

The award was presented to Mr Suresh Vazirani, CMD, Transasia Bio-Medicals Ltd by Shri Subodh Kant Sahai, Hon’ble Minister of State (Independent Charge), Ministry of Food Processing Industries, Govt. of India on 25th April’08 at a function held in Mumbai.

TRANSASIA has a 100% subsidiary in Germany, Erba Diagnostics Mannheim GmbH equipped to manufacture Instruments, Reagents and Consumables conforming to IVD Directives. It has an extensive distribution network spread over 55 countries worldwide. It is also playing a stellar role in bringing world-class products within reach of laboratories across the globe. Today, Transasia’s products enjoy a strong global presence and is exported to Italy, Germany, France, Australia, China, Turkey, USA., Latin America, Africa, Russia, Middle East, SAARC and Asia.

The Company is ISO 9001:2000 & ISO 13485:2003 certified and has been rated as India’s largest In-vitro Diagnostics Company (2006) by McEvoy & Farmer, U.S.A. (International Experts on IVD Markets).

Transasia has strategic alliances with some leading names in the diagnostic world like Sysmex Corporation-Japan, Medica-U.S.A, DiaSys-Germany, Wako-Japan, Biohit-Finland, Grifols-Spain, CAN Ag-Sweden and Diesse-Italy among others.

TRANSASIA’s mission and philosophy is to serve the doctors & patients worldwide by meeting their needs for reliable, affordable and innovative Medical Diagnostic Systems. The spirit is the “spirit of India” where it wants to make a mark in this very important Diagnostic field and make TRANSASIA a formidable force on the Diagnostic world map.

Source: Press release distribution via India PRwire

About Transasia Bio-Medicals Ltd :

TRANSASIA BIO-MEDICALS LTD.is a leader in the Clinical DiagnosticsSegment across the Indian healthcare sector, providing Total Solutions for Clinical Diagnosis. With an enviable 29-year track record in the Industry, the company is the largest Indian Manufacturer and Exporter of Diagnostic instruments. The Company has successfully developed and manufactured hi-tech In-Vitro Diagnostic (IVD) instruments & Reagents and has become a name to reckon with, in India and 55 countries across the world.

TRANSASIA’s success is totally based ontotal commitment to the customers for providing them with Quality products and services.

From its modest beginning in 1979 as a marketing firm for a few imported diagnostic equipments TRANSASIA today has the largest Sales and Installation base with over 15000, installations all over the country supported by a network of55 service centers and 14 Zonal offices at metros & major cities backedby a strong force of trained engineers and customer training personnel.

The long and arduous journey has been marked by awards and recognition from private, public and Government institutions like:

· Mr. Suresh Vazirani, CMD, Transasia, conferred with Indira Super Achiever Award from Indira Group of Institutes - 2006

· “Niryat Shree” for excellence in Exports” from FIEO, Ministry of Commerce – 2006

· ‘Most Promising SME and ‘Emerging India Awards’ from CNBC - 2005

· National R&D award for technology innovation, development and successful global commercialization for our XL range of Analyzers, India’s first and only Automated Biochemistry Analyzer – 2005

· ‘National Quality Award’ and ‘National Export Award’ in 2000

Marketing & Corporate Communications department
Sangeeta Mishra - Head- MARCOM dept.
m.sangeeta@transasia.co.in
Ph:40309000/40309022/40309021

This state-of-the-art GMP approved and ISO 9000:2000 and 14000 certified plant was supported with significant investments to the tune of Rs 40 crores.

The facility currently has the capacity to manufacture 10 million tablets, 3 million dosages of liquids and 12 lakh dosages of powder injectables. This plant has been designed to cater to an increase in demand by 25-30% without any additional major investments in the facility.

Fivedifferent veterinary healthcare formulations including Liquid and Powder injectables, Liquid orals, Tablets and External preparations like Ointments, all get manufactured in one plant. It also contains the capability to manufacture both beta lactam and non-beta lactam antibiotics in the same plant

The thrust on indigenous production at RFCL is supported by a strong backend integration with its DSIR recognized Formulation Development Laboratory and the Analytical Resource Centre situated in RFCL headquarters in Delhi. This centre has worked in tandem with every developmental step of the manufacturing facility to ensure that state-of-the-art technology transfer documents are available for all the products to be manufactured at Haridwar and meet the regulatory guidelines required for India as well as the global regulatory standards.

“It’s a great feeling to see how the team at RFCL has given a final shape to this dream project. Tremendous amount of hard work, excellent team work, and a clear focus in terms of optimizing resources has gone into it. A memorable journey of two years since the acquisition of land, this is certainly a sign of victory for each one of us as through this world class manufacturing facility we are confident of building a world class business,” said Sushil Mehta, Managing Director, RFCL on this momentous occasion.

Close on the heels of the acquisition of Bremer Pharma GmbH of Germany, this is yet another feather in the cap of RFCL in its earnest attempts to unlock the potential across all its businesses. “Integrating this manufacturing capability along with the synergistic capability that we have acquired out of Bremer Pharma in Germany puts together a significant manufacturing strength which will become a key pillar to the globalization plans of Vetnex and that of RFCL,” he adds.

The company has also initiated “Project Create”, a multi-facility, “state-of-the-art”, manufacturing plant for laboratory solutions, being set up on a 20 acre land in Panoli, Gujarat with global capacities to cater to global requirements as per International standards. This plant is expected to get commissioned in the next 15 months.

Source: Press release distribution via India PRwire

About RFCL

The 100% ICICI Venture owned, RFCL covers the expanse of Life Sciences industries including pharmaceuticals, biotechnology, R&D laboratories, food processing, in vitro diagnostic facilities in clinical labs, hospitals, nursing homes and animal health care industry through its four Strategic Business Units: Rankem, Diagnova, Vetnex and Neosynth. RFCL has evolved its corporate philosophy arou